Cuprina Holdings (Cayman) LTD
No SEC Form 4 filings for $CUPR in the last 30 days.
See all $CUPR insider activity →Cuprina Holdings (CUPR), a Singapore-based wound care company, priced its Nasdaq IPO at $1.15 per share, raising $5 million. R.F. Lafferty is the sole underwriter, which may limit liquidity and impact early trading.
Super Copper Corp. (CSE: CUPR, OTCQB: CUPPF) said it is mobilizing for a maiden diamond drill program at the El Alto target in Chile, planning up to 15 holes and about 5,000 m to test an 800 m-plus chargeability corridor. It reported Phase 1 geophysics completed at Castilla and said it is fully funded after a March 2026 financing. It also outlined a 15-month biopolymer R&D program for copper processing and remediation.
The article highlights premarket moves in several stocks, including Cuprina Holdings, CEA Industries, Absci and Wendy’s, as of 7:10 a.m. ET. It also notes Cuprina said it received U.S. FDA 510(k) clearance for its MEDIFLY maggot debridement product, according to a company release.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CUPR (Cuprina Holdings (Cayman) LTD). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CUPR coverage spans financial news, market movers and regulation.
First‑day pricing creates immediate trading opportunity; thin liquidity may cause volatile price swings.
Near-term catalyst is the start of maiden drilling and ongoing geophysics, supported by stated funding; near-term trading likely follows drill-readiness and financing credibility.
FDA 510(k) clearance is a concrete regulatory milestone that can improve commercialization prospects and near-term sentiment.
Regulatory clearance supports commercialization of MEDIFLY and reduces regulatory uncertainty for the product line.
FDA clearance for a second MDT larvae species can improve commercial defensibility and adoption optionality, but the article provides no financial metrics or timeline.
AlphAI scores every news story that mentions CUPR with an AI model for sentiment and relevance, and aggregates insider trades from Cuprina Holdings (Cayman) LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cuprina Holdings (CUPR), a Singapore-based wound care company, priced its Nasdaq IPO at $1.15 per share, raising $5 million. R.F. Lafferty is the sole underwriter, which may limit liquidity and impact early trading.
1 min readSuper Copper Corp. (CSE: CUPR, OTCQB: CUPPF) said it is mobilizing for a maiden diamond drill program at the El Alto target in Chile, planning up to 15 holes and about 5,000 m to test an 800 m-plus chargeability corridor. It reported Phase 1 geophysics completed at Castilla and said it is fully funded after a March 2026 financing. It also outlined a 15-month biopolymer R&D program for copper processing and remediation.
7 min readThe article highlights premarket moves in several stocks, including Cuprina Holdings, CEA Industries, Absci and Wendy’s, as of 7:10 a.m. ET. It also notes Cuprina said it received U.S. FDA 510(k) clearance for its MEDIFLY maggot debridement product, according to a company release.
2 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min readThe FDA cleared Cuprina Holdings’ second fly species for maggot wound therapy, the company said. Along with Lucilia sericata (cleared since 2004), Cuprina received clearance for Lucilia cuprina (Australian sheep blowfly). Cuprina said it is the only company with FDA clearance for two larvae species; it made no claim of major therapeutic differences.
6 min readRegentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
6 min readCuprina Holdings (Cayman) Limited (CUPR) shares rose about 114% on Friday after the company regained compliance with Nasdaq Capital Markets listing requirements, according to the report. The stock traded around $5.16, up 114.12%, after opening at $3.26 and reaching an intraday high of $8.23.
2 min readCuprina Holdings (Cayman) (NASDAQ:CUPR) shares rose 49.3% on Thursday, trading between $3.70 and $3.30 after closing at $2.21. Volume was 3.16M shares, up 2,429% vs. average. Weiss Ratings reaffirmed a “sell (e+)” rating. The company reported Q1 EPS of -$0.40 on revenue of $0.01M.
4 min readSINGAPORE, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Cuprina Holdings ( Cayman ) Limited ( Nasdaq: CUPR ) ( "Cuprina" or "the Company" ) , a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of ...
3 min readU.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Wednesday. The Dow traded down 0.56% to 45,456.80 while the NASDAQ rose 0.12% to 21,905.19. The S&P 500 also rose, gaining, 0.30% to 6,532.40. Information technology shares jumped by 2.2% on ...
3 min read
